Hvivo Plc (HVO) Ord 0.1p

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
hVIVO acquires biological material storage specialist Cryostore
27 February 2025 15:13
(Sharecast News) - hVIVO announced the acquisition of Cryostore, a specialist provider of temperature-controlled storage solutions for biological and clinical materials, for up to £3.2m on Thursday.
-
Hvivo signs £2m contract with new biopharma client
17 February 2025 11:45
(Sharecast News) - Contract research organisation Hvivo said on Monday that it has signed a £2.0m contract with a new biopharmaceutical client to complete the final stage of a characterisation study ahead...
-
hVIVO reports positive results from Shionogi RSV trial
5 February 2025 10:19
(Sharecast News) - hVIVO reported positive results from a phase 2a respiratory syncytial virus (RSV) human challenge trial conducted on behalf of Shionogi on Wednesday.
-
hVIVO signs human challenge trial contract with Inhalon Biopharma
3 February 2025 07:48
(Sharecast News) - hVIVO announced on Monday that it has signed a contract with Inhalon Biopharma to conduct a human challenge trial assessing the efficacy of IN-002, an inhaled antiviral candidate for...
-
Hvivo acquires two clinical research units, FY revenues up 11.9pc
29 January 2025 09:15
(Sharecast News) - Contract research organisation Hvivo said on Wednesday that it has acquired two clinical research units from German outfit CRS Clinical Research Services.
-
hVIVO signs LOI to conduct pivotal whooping cough study
27 January 2025 12:28
(Sharecast News) - hVIVO announced on Monday that it has signed a letter of intent with ILiAD Biotechnologies to conduct a pivotal phase three human challenge trial for ILiAD's lead whooping cough...
-
hVIVO secures largest standalone lab contract to date
21 January 2025 14:27
(Sharecast News) - hVIVO announced on Tuesday that it has secured its largest standalone laboratory contract to date, with its hLAB division signing a £2.7m deal with a US-based biotechnology client,...
-
hVIVO completes pilot study for hMPV challenge model
13 January 2025 14:40
(Sharecast News) - Contract research organisation and human challenge trial specialist hVIVO announced the successful completion of a pilot characterisation study for its human metapneumovirus (hMPV)...
-
Hvivo strikes £11.5m RSV contract with existing client
10 December 2024 08:01
(Sharecast News) - Contract research organisation Hvivo has struck a £11.5m Respiratory Syncytial Virus contract with an "existing top-tier global pharmaceutical client".
-
hVIVO upbeat on positive human challenge trial results with client
7 October 2024 10:21
(Sharecast News) - Specialist contract research organisation hVIVO announced positive results from a phase 2a human challenge trial (HCT) for Enanta Pharmaceuticals' RSV antiviral candidate, EDP-323, on...
-
hVIVO gets HSE clearance, launches new lab services
30 September 2024 10:19
(Sharecast News) - Specialist contract research organisation hVIVO launched the full suite of services provided by its hLAB division - a highly specialised virology and immunology laboratory supporting...
-
Hvivo delivers record revenues in H1, reiterates FY guidance
17 July 2024 08:46
(Sharecast News) - Contract research organisation Hvivo restated full-year guidance on Wednesday as the group revealed it had delivered record revenues in H1.
Company announcements Announcements
-
AIM Rule 17 and Schedule 2(g) Update
26 March 2025 13:51
Hvivo
-
Notice of Results
21 March 2025 07:00
Hvivo
-
Director/PDMR Shareholding
7 March 2025 07:00
Hvivo
-
Acquisition of Cryostore for up to £3.2m
27 February 2025 07:00
Hvivo
-
£2m hMPV characterisation study contract
17 February 2025 07:00
Hvivo
-
Shionogi reports positive RSV trial results
5 February 2025 07:00
Hvivo
-
RSV contract signed with Inhalon Biopharma
3 February 2025 07:00
Hvivo
-
Holding(s) in Company
31 January 2025 13:24
Hvivo
-
Holding(s) in Company
31 January 2025 07:00
Hvivo
-
Acquisition: two Clinical Research Units from CRS
29 January 2025 07:01
Hvivo
-
Trading update
29 January 2025 07:00
Hvivo
-
LOI signed for Phase 3 Whooping Cough trial
27 January 2025 07:00
Hvivo
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.